Advertisement

Topics

Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 Pipeline Review, H1 2018 [Report Updated: 15062018] Prices from USD $3500

15:41 EDT 17 Sep 2018 | BioPortfolio Report Blog

Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 Pipeline Review, H1 2018


Summary


Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 Mitogenactivated protein kinase kinase kinase 5 MAP3K5 is a member of MAP kinase kinase kinase family encoded by MAP3K5 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signaling for determination of cell fate such as differentiation and survival. It plays a crucial role in the apoptosis signal transduction pathway through mitochondriadependent caspase activation. It is essential for host defense against a wide range of pathogens. It mediates signal transduction of various stressors like oxidative stress as well as by receptormediated inflammatory signals.


Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 5 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Gastrointestinal, Immunology, Toxicology, Genito Urinary System And Sex Hormones, Metabolic Disorders, Oncology and Undisclosed which include indications Drug Toxicity, Hepatic Injury, Myocardial Infarction, Neurodegenerative Diseases, NonAlcoholic Steatohepatitis NASH, Acute Renal Failure ARF Acute Kidney Injury, Alcoholic Hepatitis, Amyotrophic Lateral Sclerosis, Cardiovascular Disease, Chronic Pain, Diabetic Nephropathy, Gastric Cancer, Hepatic Encephalopathy, Inflammation, Liver Diseases, Non Alcoholic Fatty Liver Disease NAFLD, Pulmonary Hypertension, Rheumatoid Arthritis, Thrombosis and Unspecified.


The latest report Mitogen Activated Protein Kinase Kinase Kinase 5 Pipeline Review, H1 2018, outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.


Scope


The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25

The report reviews Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 targeted therapeutics and enlists all their major and minor projects

The report assesses Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 Pipeline Review, H1 2018 [Report Updated: 15062018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Mitogen Activated Protein Kinase Kinase Kinase 5 Apoptosis Signal Regulating Kinase 1 or MAPK/ERK Kinase Kinase 5 or MAP3K5 or EC 2.7.11.25 Pipeline Review, H1 2018 [Report Updated: 15062018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...